Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 115

1.

Facial nerve repair: the impact of technical variations on the final outcome.

Sánchez-Ocando M, Gavilán J, Penarrocha J, González-Otero T, Moraleda S, Roda JM, Lassaletta L.

Eur Arch Otorhinolaryngol. 2019 Dec;276(12):3301-3308. doi: 10.1007/s00405-019-05638-8. Epub 2019 Sep 19.

PMID:
31538238
2.

Assessment of Overall Survival in Glioma Patients as Predicted by Metabolomic Criteria.

Gandía-González ML, Cerdán S, Barrios L, López-Larrubia P, Feijoó PG, Palpan A Jr, Roda JM, Solivera J.

Front Oncol. 2019 May 10;9:328. doi: 10.3389/fonc.2019.00328. eCollection 2019.

3.

Facial paralysis: Clinical practice guideline of the Spanish Society of Otolaryngology.

Lassaletta L, Morales-Puebla JM, Altuna X, Arbizu Á, Arístegui M, Batuecas Á, Cenjor C, Espinosa-Sánchez JM, García-Iza L, García-Raya P, González-Otero T, Mañós M, Martín C, Moraleda S, Roda JM, Santiago S, Benítez J, Cavallé L, Correia V, Estévez JM, Gómez J, González R, Jiménez J, Lacosta JL, Lavilla MJ, Peñarrocha J, Polo R, García-Purriños F, Ramos F, Tomás M, Uzcanga M, Vallejo LÁ, Gavilán J.

Acta Otorrinolaringol Esp. 2020 Mar - Apr;71(2):99-118. doi: 10.1016/j.otorri.2018.12.004. Epub 2019 May 13. English, Spanish.

4.

Early toll-like receptor 4 blockade reduces ROS and inflammation triggered by microglial pro-inflammatory phenotype in rodent and human brain ischaemia models.

Parada E, Casas AI, Palomino-Antolin A, Gómez-Rangel V, Rubio-Navarro A, Farré-Alins V, Narros-Fernandez P, Guerrero-Hue M, Moreno JA, Rosa JM, Roda JM, Hernández-García BJ, Egea J.

Br J Pharmacol. 2019 Aug;176(15):2764-2779. doi: 10.1111/bph.14703. Epub 2019 Jun 17.

PMID:
31074003
5.

Update on the pathophysiology and management of syringomyelia unrelated to Chiari malformation.

Giner J, Pérez López C, Hernández B, Gómez de la Riva Á, Isla A, Roda JM.

Neurologia. 2019 Jun;34(5):318-325. doi: 10.1016/j.nrl.2016.09.010. Epub 2016 Dec 9. Review. English, Spanish.

6.

Evolution of Patients With Immediate Complete Facial Paralysis Secondary to Acoustic Neuroma Surgery.

Pardo-Maza A, Lassaletta L, González-Otero T, Roda JM, Moraleda S, Arbizu Á, Gavilán J.

Ann Otol Rhinol Laryngol. 2016 Jun;125(6):495-500. doi: 10.1177/0003489415624700. Epub 2015 Dec 30.

PMID:
26719351
7.

Small synthetic hyaluronan disaccharides afford neuroprotection in brain ischemia-related models.

Egea J, Parada E, Gómez-Rangel V, Buendia I, Negredo P, Montell E, Ruhí R, Vergés J, Roda JM, García AG, López MG.

Neuroscience. 2014 Apr 18;265:313-22. doi: 10.1016/j.neuroscience.2014.01.032. Epub 2014 Jan 28.

PMID:
24486437
8.

End-to-Side interposed donor grafting as a facial nerve reinforcement technique after vestibular schwannoma surgery.

Celis-Aguilar E, Lassaletta L, Roda JM, Gavilán J.

Ann Otol Rhinol Laryngol. 2013 Aug;122(8):520-3.

PMID:
24027862
9.

NF2 genetic alterations in sporadic vestibular schwannomas: clinical implications.

Lassaletta L, Torres-Martín M, Peña-Granero C, Roda JM, Santa-Cruz-Ruiz S, Castresana JS, Gavilan J, Rey JA.

Otol Neurotol. 2013 Sep;34(7):1355-61. doi: 10.1097/MAO.0b013e318298ac79.

PMID:
23921927
10.

Fcγ receptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies.

Justiniano SE, Elavazhagan S, Fatehchand K, Shah P, Mehta P, Roda JM, Mo X, Cheney C, Hertlein E, Eubank TD, Marsh C, Muthusamy N, Butchar JP, Byrd JC, Tridandapani S.

J Biol Chem. 2013 Sep 13;288(37):26800-9. doi: 10.1074/jbc.M113.485185. Epub 2013 Jul 31.

11.

Novel multitarget ligand ITH33/IQM9.21 provides neuroprotection in in vitro and in vivo models related to brain ischemia.

Lorrio S, Gómez-Rangel V, Negredo P, Egea J, Leon R, Romero A, Dal-Cim T, Villarroya M, Rodriguez-Franco MI, Conde S, Arce MP, Roda JM, García AG, López MG.

Neuropharmacology. 2013 Apr;67:403-11. doi: 10.1016/j.neuropharm.2012.12.001. Epub 2012 Dec 7.

PMID:
23228428
12.

Tinnitus and quality of life following vestibular schwannoma surgery.

Del Río L, Lassaletta L, Díaz-Anadón A, Alfonso C, Roda JM, Gavilán J.

B-ENT. 2012;8(3):167-71.

PMID:
23113378
13.

Hypoxia inducible factors-mediated inhibition of cancer by GM-CSF: a mathematical model.

Chen D, Roda JM, Marsh CB, Eubank TD, Friedman A.

Bull Math Biol. 2012 Nov;74(11):2752-77. doi: 10.1007/s11538-012-9776-3. Epub 2012 Oct 17.

14.

Clinical management guidelines for subarachnoid haemorrhage. Diagnosis and treatment.

Vivancos J, Gilo F, Frutos R, Maestre J, García-Pastor A, Quintana F, Roda JM, Ximénez-Carrillo A; por el Comité ad hoc del Grupo de Estudio de Enfermedades Cerebrovasculares de la SEN:, Díez Tejedor E, Fuentes B, Alonso de Leciñana M, Alvarez-Sabin J, Arenillas J, Calleja S, Casado I, Castellanos M, Castillo J, Dávalos A, Díaz-Otero F, Egido JA, Fernández JC, Freijo M, Gállego J, Gil-Núñez A, Irimia P, Lago A, Masjuan J, Martí-Fábregas J, Martínez-Sánchez P, Martínez-Vila E, Molina C, Morales A, Nombela F, Purroy F, Ribó M, Rodríguez-Yañez M, Roquer J, Rubio F, Segura T, Serena J, Simal P, Tejada J.

Neurologia. 2014 Jul-Aug;29(6):353-70. doi: 10.1016/j.nrl.2012.07.009. Epub 2012 Oct 6. English, Spanish.

15.

Stabilization of HIF-2α induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model.

Roda JM, Wang Y, Sumner LA, Phillips GS, Marsh CB, Eubank TD.

J Immunol. 2012 Sep 15;189(6):3168-77. doi: 10.4049/jimmunol.1103817. Epub 2012 Aug 6.

16.

CDP-choline at high doses is as effective as i.v. thrombolysis in experimental animal stroke.

Gutiérrez-Fernández M, Leciñana MA, Rodríguez-Frutos B, Ramos-Cejudo J, Roda JM, Díez-Tejedor E.

Neurol Res. 2012 Sep;34(7):649-56. doi: 10.1179/1743132812Y.0000000058. Epub 2012 Jun 22.

PMID:
22732142
17.

Hypoxia-inducible factor-2α regulates GM-CSF-derived soluble vascular endothelial growth factor receptor 1 production from macrophages and inhibits tumor growth and angiogenesis.

Roda JM, Sumner LA, Evans R, Phillips GS, Marsh CB, Eubank TD.

J Immunol. 2011 Aug 15;187(4):1970-6. doi: 10.4049/jimmunol.1100841. Epub 2011 Jul 15.

18.

Human cadaver brain infusion skull model for neurosurgical training.

Olabe J, Olabe J, Roda JM, Sancho V.

Surg Neurol Int. 2011;2:54. doi: 10.4103/2152-7806.80119. Epub 2011 Apr 28.

19.

Reversible posterior leukoencephalopathy syndrome after lateral skull base surgery.

Sanchez-Cuadrado I, Lassaletta L, Royo A, Cerdeño V, Roda JM, Gavilán J.

Otol Neurotol. 2011 Jul;32(5):838-40. doi: 10.1097/MAO.0b013e31821f1b95.

PMID:
21659926
20.

IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production.

Jaime-Ramirez AC, Mundy-Bosse BL, Kondadasula S, Jones NB, Roda JM, Mani A, Parihar R, Karpa V, Papenfuss TL, LaPerle KM, Biller E, Lehman A, Chaudhury AR, Jarjoura D, Burry RW, Carson WE 3rd.

J Immunol. 2011 Mar 15;186(6):3401-9. doi: 10.4049/jimmunol.1000328. Epub 2011 Feb 14.

Supplemental Content

Support Center